Riskpilot← Back to searchSign inGet full accessApomera AB
ABActiveOrg 5569582058Ranhammarsvägen 20Other non-specialised retail sale · NACE 4712Est. 20149 employees
Revenue 2024
SEK 2,8M
-88% vs 2023
EBITDA margin
-34.2%
+89% vs 2023
Equity ratio
73.3%
Financial strength
Net profit 2024
SEK -988K
+89% vs 2023
| Revenue | SEK 2,8M | -88% |
| EBITDA | SEK -973K | +89% |
| Net profit | SEK -988K | +89% |
| Total assets | SEK 1,4M | -94% |
| Equity | SEK 1M | -94% |
| Employees | 9 | — |
Legal name
Apomera AB
Org number
5569582058
Legal form
Aktiebolag
NACE code
4712 · Other non-specialised retail sale
Founded
13 januari 2014
Share capital
SEK 119 000
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Styrelsen ska bestå av 4 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Bolaget skall bedriva handel med apoteksvaror, egenvårdsprodukter (OTC-läkemedel) och icke receptföreskrivna läkemedel samt därmed förenlig verksamhet.
Address
Ranhammarsvägen 20
Email
magnus.jopevi@renevatio.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 10 421 | 8 150 | 3 099 | 4 174 | 9 837 | 20 601 | 23 665 | 2 843 |
| Staff expenses | — | — | — | — | — | — | — | — | −5 204 | −416 |
| EBITDA | −1 091 | −2 424 | −4 916 | −3 318 | −5 998 | −8 054 | −10 555 | −14 602 | −9 232 | −973 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| EBIT | −1 091 | −2 424 | −4 916 | −3 318 | −5 998 | −8 054 | −10 555 | −14 602 | −9 232 | −973 |
| Net financials | −20 | −22 | −84 | −139 | −18 | −72 | −132 | −235 | −14 | −15 |
| Profit before tax | −1 111 | −2 446 | −5 000 | −3 457 | −6 015 | −8 126 | −10 687 | −14 837 | −9 246 | −988 |
| Tax | −0 | −0 | −0 | −0 | −0 | −112 | −0 | −0 | — | — |
| Net profit | −1 111 | −2 446 | −5 000 | −3 457 | −6 015 | −8 238 | −10 687 | −14 837 | −9 246 | −988 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3 831 | 1 877 | 5 166 | 8 108 | 2 614 | 2 196 | 4 030 | 13 238 | 22 016 | 1 407 |
| Equity | 2 874 | 427 | 1 113 | 6 540 | 525 | −2 315 | −583 | 10 009 | 18 282 | 1 031 |
| Long-term debt | 350 | 310 | 310 | 250 | 250 | 250 | 250 | 0 | — | — |
| Short-term debt | 607 | 1 140 | 3 743 | 1 318 | 1 839 | 4 261 | 4 363 | 3 229 | 3 734 | 376 |
| Total debt | 957 | 1 450 | 4 053 | 1 568 | 2 089 | 4 511 | 4 613 | 3 229 | 3 734 | 376 |
EBITDA margin
-34.2%
This company
15.8%
Market median
-316% vs market
20152024
Equity ratio
73.3%
This company
38.2%
Market median
+92% vs market
20152024
Return on equity
-95.8%
This company
18.4%
Market median
-621% vs market
20152024
Net profit margin
-34.8%
This company
8.1%
Market median
-530% vs market
20152024
Asset turnover
2.02×
This company
1.12×
Market median
+80% vs market
20152024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LH | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Renevatio Aktiebolag | Company | 53.0% | 53.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Renevatio Aktiebolag
Apomera AB Board members of Apomera AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Henrik Johansson | Audit | 0 companies |
| Jöns Mikko Erik Andersson | Chairman | 0 companies |
| Sami Johannes Vikback | Board of Directors | 0 companies |
| Björn Erik Thornquist | Board of Directors | 0 companies |
| Martin Oscar Peter Fredriksson | Board of Directors | 0 companies |
| Sarah Margit Lovisa Ahnström | Board of Directors | 0 companies |
| Gunnar Selving | Board of Directors | 0 companies |
| Diana Selguson | Board of Directors | 0 companies |
| Magnus Bertil Jopevi | Chairman | 0 companies |
| Lars Erik Niklas Eriksson | Deputy Board Member | 0 companies |